1. Home
  2. WGSWW vs FRA Comparison

WGSWW vs FRA Comparison

Compare WGSWW & FRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WGSWW
  • FRA
  • Stock Information
  • Founded
  • WGSWW 2017
  • FRA 2003
  • Country
  • WGSWW United States
  • FRA United States
  • Employees
  • WGSWW 1000
  • FRA N/A
  • Industry
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • FRA Investment Bankers/Brokers/Service
  • Sector
  • WGSWW Technology
  • FRA Finance
  • Exchange
  • WGSWW Nasdaq
  • FRA Nasdaq
  • Market Cap
  • WGSWW N/A
  • FRA N/A
  • IPO Year
  • WGSWW N/A
  • FRA N/A
  • Fundamental
  • Price
  • WGSWW $0.06
  • FRA $12.57
  • Analyst Decision
  • WGSWW
  • FRA
  • Analyst Count
  • WGSWW 0
  • FRA 0
  • Target Price
  • WGSWW N/A
  • FRA N/A
  • AVG Volume (30 Days)
  • WGSWW 36.6K
  • FRA 165.4K
  • Earning Date
  • WGSWW 02-18-2025
  • FRA 01-01-0001
  • Dividend Yield
  • WGSWW N/A
  • FRA 11.06%
  • EPS Growth
  • WGSWW N/A
  • FRA N/A
  • EPS
  • WGSWW N/A
  • FRA N/A
  • Revenue
  • WGSWW $305,450,000.00
  • FRA N/A
  • Revenue This Year
  • WGSWW N/A
  • FRA N/A
  • Revenue Next Year
  • WGSWW N/A
  • FRA N/A
  • P/E Ratio
  • WGSWW N/A
  • FRA N/A
  • Revenue Growth
  • WGSWW 50.79
  • FRA N/A
  • 52 Week Low
  • WGSWW $0.17
  • FRA $11.33
  • 52 Week High
  • WGSWW $0.21
  • FRA $13.10
  • Technical
  • Relative Strength Index (RSI)
  • WGSWW N/A
  • FRA 55.43
  • Support Level
  • WGSWW N/A
  • FRA $12.49
  • Resistance Level
  • WGSWW N/A
  • FRA $12.64
  • Average True Range (ATR)
  • WGSWW 0.00
  • FRA 0.12
  • MACD
  • WGSWW 0.00
  • FRA 0.06
  • Stochastic Oscillator
  • WGSWW 0.00
  • FRA 89.85

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Share on Social Networks: